Skip to main content

Cognition Therapeutics, Inc.

corporate_fare Company Profile

Cognition Therapeutics, Inc.

CGTX·NASDAQ·Life Sciences·CIK 0001455365

The company is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. Many of these diseases currently have limited or no approved therapies. The company aims to develop disease-modifying treatments for patients with these degenerative disorders. Its lead product candidate is zervimesine, also known as CT1812, an orally delivered small molecule. Zervimesine is designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including β-amyloid (Aβ) and ɑ-synuclein, which are linked to diseases like Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). The United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024. The company initially focused on developing zervimesine for AD, believing it displaces Aβ oligomers from neuronal receptors, potentially slowing synapse loss and cognitive decline in AD. Direct healthcare costs for AD and other dementias in the United States are estimated to exceed $350 billion, with approximately 7 million people diagnosed with AD in the U.S. and an estimated 35 million globally. Top-line results from the Phase 2 COG0201 (SHINE) study of zervimesine in mild-to-moderate AD were reported in 2024. Enrollment is ongoing in the COG0203 (START) Phase 2 study of zervimesine for patients with Mild Cognitive Impairment (MCI) and early-stage AD. The START clinical trial is conducted in collaboration with the Alzheimer's Clinical Trial Consortium (ACTC) and both studies are supported by grant awards totaling $110 million from the National Institute of Aging (NIA).

Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CGTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Cognition Therapeutics Completes Productive FDA Type C Meeting for Zervimesine in Dementia with Lewy Bodies

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$23.49M
Diluted EPS
-$0.32
Op. Cash Flow
-$24.59M
Operating Income
-$47.8M
Cash & Equivalents
$36.81M
Debt / Equity
0.00×
Shares Outstanding
88.9M sh
Source: 10-K · filed 2026-03-26 · accession 0001104659-26-034880
$0.58 -0.38% today
52-week range · as of 2026-11-05 $0.5501 – $1.82
Market cap
$55.37M
Volume
665.4K (1.2× avg)
3-mo avg 550.8K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CGTX - Filings & News (Page 2)

CGTX
Jan 27, 2026, 7:37 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $0.580 info
Change: -$0.820 (-59%) info
Market Cap: $55.368M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets